Search academic texts

Information × Registration Number 0213U001462, 0111U000376 , R & D reports Title To explore possibility of radionuclide therapy and diagnostic in coplex treatment and monitoring of medullary cancer patients popup.stage_title Head Solodyannikova Oksana Ivanovna, Registration Date 21-02-2013 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study - 45 patients with medullary thyroid cancer. Purpose - to improve treatment and to determine possible methods of radionuclide diagnostics for monitoring patients with medullary thyroid cancer (MRSCHZ) and develop an algorithm radionuclide monitoring of this category of patients. Methods and techniques - scanning the entire body with 99mTc-karbomekom, dynamic scintigraphy with 99mTc-karbomekom, radionuclide therapy with 131I-MIBG, statistics, dvohdetektorna gamma camera company "Mediso" (Hungary), single photon emission computed tomography (SPECT) "E. CAM 180 ".The algorithm using the methods of radionuclide diagnostics umonitorynhu patients MRSCHZ. Specified and optimized dose of activity in the course of treatment studies of treatments and the duration of the period between the treatment courses by studying the characteristics of dosimetry and pharmacokinetics biorozpodilu radiopharmaceuticals (RFP). Treated 10 patients on MRSCHZ. A protocol diagnostic scan with 99mTc-karbomekom (based dymerkaptoyantarna acid) to be used in the future for monitoring patients MRSCHZ, including the group of patients after surgical treatment and systemic radionuclide therapy. A scintigraphic examination with 99mTc-karbomekom 20 patients. The peculiarities of pharmacokinetics and biorozpodilu 99mTc-karbomeka MRSCHZ in patients after surgical treatment. A physical and technical support procedures to quantitative characteristics of dynamic scintigraphy with 99mTc-karbomekom. It is shown that the method of diagnostic scan with 99mTc-karbomekom can be used for the detection of recurrences and metastatic lesions at the stage of monitoring patients MRSCHZ. The possibility of the use of 131I-MIBG in therapeutic doses in the treatment MRSCHZ. Found that for improving diagnostic efficiency indices scintigraphic study in patients with MRSCHZ advisable to scintigraphy or SPECT with 99mTc-karbomekom at postoperative monitoring of patients in the time interval 30-60 min after administration vnutrishnovvennoho RFP. We prove that the conduct of indirect radionuclide angiography and dynamic scintigraphy after intravenous 99mTc-karbomeka allows more information to be differential diagnostic value and can improve the specificity of the study. The place of radionuclide diagnostics methods to monitor patients MRSCHZ. Product Description popup.authors Даниленко Вікторія Вікторівна Джужа Дмитро Олександрович Михайленко Валерій Євгенович Сукач Георгій Георгійович popup.nrat_date 2020-04-02 Close